RESUMO
A renewed interest in the use of ß-blockers for neurodevelopmental disorders has recently resurfaced, notably as an addition to the limited psychopharmacological armamentarium of autism spectrum disorders (ASD). In this clinical perspective, authors decently argue this use could be advantageous and multi-folded for this population.
Assuntos
Transtorno do Espectro Autista , Transtorno Autístico , Humanos , Transtorno Autístico/tratamento farmacológico , Transtorno do Espectro Autista/tratamento farmacológicoRESUMO
ABSTRACT: In the aftermath of COVID-19, it sounds equally important, on the part of mental health providers to undertake the onerous duty of promoting resilience, to empower individuals, foster their own natural strengths, and help them incorporate new coping strategies into their everyday lives at this exceptional moment of hardship.
Assuntos
Adaptação Psicológica , COVID-19/psicologia , Resiliência Psicológica , COVID-19/epidemiologia , Felicidade , Humanos , Pandemias , SARS-CoV-2Assuntos
Aripiprazol/administração & dosagem , Cloridrato de Duloxetina/administração & dosagem , Esquizofrenia/tratamento farmacológico , Adolescente , Antipsicóticos/administração & dosagem , Dopaminérgicos/administração & dosagem , Quimioterapia Combinada , Humanos , Masculino , Esquizofrenia/fisiopatologia , Resultado do TratamentoRESUMO
Cognitive dysfunction in MDD is more of an endophenotype rather than an epiphenomenon. This sorely remains un face cachee of MDD and largely unimpacted by currently available pharmacological and non-pharmacological interventions. These deficits have been considerably tied to symptoms residua, increased risk of relapse, functional impairment, and, reduced quality of life. Accordingly, targeting cognitive symptoms domain in MDD is unmet clinical desideratum in the journey to functional recovery.
